Bristol Myers touts early social and environmental progress among achievements in latest ESG report

Beth Snyder Bulik

Senior Editor

A boost for diversity in clinical trials and an earlier-than-expected $1 billion spend with minority-owned businesses are some of the highlights in Bristol Myers Squibb’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers touts early social and environmental progress among achievements in latest ESG report

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Bris­tol My­ers touts ear­ly so­cial and en­vi­ron­men­tal progress among achieve­ments in lat­est ESG re­port

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Bristol Myers touts early social and environmental progress among achievements in latest ESG report